In the evolving landscape of diabetes management, novel therapies like semaglutide and retatrutide are gaining traction. These drugs, belonging to the glucagon-like peptide-1 (GLP-1) receptor agonist group, offer https://amaanpqmt182567.iyublog.com/37945850/semaglutide-vs-retatrutide-a-novel-comparison-in-diabetes-management